Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase 2 2Phase 3 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Genitourinary 1

Conditions

Neoplasm Metastasis 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Gemcitabine 5Capecitabine 4pembrolizumab 3Fluorouracil 3Cisplatin 3vinflunine 2enzalutamide 2cabazitaxel 2abiraterone 2Ipilimumab 2Haloperidol 2Androgen Antagonists 2vedolizumab 1trifluridine tipiracil drug combination 1relugolix 1racemetyrosine 1nimotuzumab 1nilutamide 1lanreotide 1histrelin 1futibatinib 1exemestane 1dexamethasone acetate 1dexamethasone 21-phosphate 1bicalutamide 1beta-Glucans 1auricularum 1atezolizumab 1apatinib 1apalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Neoplasm Metastasis × vinflunine × Clear all
NCT00389155 2015-12-07

First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy

Bristol-Myers Squibb

Phase 2/3 Completed
34 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT01830231 2014-01-28

Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU)

Associació per a la Recerca Oncologica, Spain

Phase 2/3 Unknown
372 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡